文献速递临床微生物质量管理与危急值

当代肠杆菌目分离株评估哌拉西林-他唑巴坦纸片提示需优化纸片强度

Evaluation of piperacillin-tazobactam disks using contemporary Enterobacterales isolates suggests the need for disk potency optimization.
PubMed 文献 · J Clin Microbiol · 2025-01-10

该研究用100株当代肠杆菌目分离株(含40株产OXA-1)评估哌拉西林-他唑巴坦(TZP)纸片扩散法。与CLSI折点的参考肉汤微量稀释法相比,100/10 μg纸片分类一致率68%,30/6 μg纸片对EUCAST折点一致率88%,新20/5 μg纸片对CLSI折点一致率81%。降低纸片强度可改善性能,但无纸片达到最优。

要点

  • 100/10 μg TZP纸片对当代肠杆菌目分离株分类一致率仅68%,主要错误率32%。
  • 30/6 μg纸片对EUCAST折点一致率88%,但极重大错误率15%。
  • 新20/5 μg纸片对CLSI折点一致率81%,对产OXA-1菌株分离最佳。

核心结论

  • 降低TZP纸片强度可改善纸片扩散法性能及敏感与非敏感菌株的分离,尤其对产OXA-1菌株,但无纸片获得最优结果。

研究设计与样本

  • 纸片质量滴定研究,使用100株当代肠杆菌目分离株,其中40株携带blaOXA-1。

主要发现

  • 100/10 μg纸片对CLSI折点的分类一致率为68%,重大错误率0.6%,次要错误率32%。
  • 30/6 μg纸片对EUCAST折点的分类一致率为88%,极重大错误率15%,重大错误率10%。
  • 20/5 μg纸片对CLSI MIC折点和误差率有界法生成的纸片折点的分类一致率为81%。
  • 产OXA-1菌株中,100/10、30/6和20/5 μg纸片的分类一致率分别为62.4%、63.2%和70.9%。
  • 非产OXA-1菌株中,100/10、30/6和20/5 μg纸片的分类一致率分别为71.6%、86.9%和83.1%。

关键数值与推荐

  • CLSI于2022年更新肠杆菌目TZP MIC折点。
  • TZP临床折点MIC为8/4-16/4 μg/mL。
  • 100/10 μg纸片由美国FDA和CLSI标准采用,30/6 μg纸片由EUCAST开发。

临床怎么用

  • 实验室应了解当前TZP纸片扩散法对产OXA-1菌株的准确性有限。
  • 纸片强度优化可能改善TZP敏感性检测,但需更多研究确定最佳纸片。

局限性

  • 需要更大规模的多中心研究进一步优化,但缺乏资金支持。
  • 研究仅纳入100株分离株,可能限制普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Piperacillin-tazobactam (TZP) is a commonly used broad-spectrum agent. OXA-1 β-lactamases drive global Enterobacterales TZP resistance and raise MICs to the clinical breakpoints (8/4-16/4 µg/mL), making susceptibility testing challenging. Two TZP disks are used globally. The first with 100 µg piperacillin and 10 µg tazobactam, established in 1992, is used by laboratories following U.S. FDA and Clinical and Laboratory Standards Institute (CLSI) standards. The second, with 30 µg piperacillin and 6 µg tazobactam, was developed by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). When CLSI updated Enterobacterales TZP MIC breakpoints in 2022, it became apparent that the 100/10 µg disk may not accurately predict TZP resistance or susceptibility. In this study, we performed a disk mass titration study using 100 contemporary Enterobacterales isolates, including 40 harboring blaOXA-1. Relative to reference broth microdilution with CLSI breakpoints, categorical agreement (CA) for the 100/10 µg disk was 68% with 0.6% major errors (MEs) and 32% minor errors. The CA for the 30/6 µg disk against EUCAST breakpoints was 88% with 15% very major errors and 10% ME. A third disk developed in this study, 20/5 µg, yielded 81% CA with CLSI MIC breakpoints and disk breakpoints generated using the error-rate-bounded method. CA was 62.4%, 63.2%, and 70.9% for isolates with blaOXA-1 using the 100/10, 30/6, and 20/5 µg disks, respectively, whereas it was 71.6%, 86.9%, and 83.1% for isolates without blaOXA-1. Decreasing TZP disk potency improved the overall performance of disk diffusion and improved separation between susceptible and non-susceptible isolates, particularly those harboring OXA-1, but no disk yielded optimal results. IMPORTANCE: In this article, we address major gaps in contemporary data for piperacillin-tazobactam (TZP) susceptibility testing and evaluate the performance of disk diffusion. TZP is the most common empiric broad-spectrum agent against Gram-negative pathogens and is used as a carbapenem-sparing regimen. OXA-1 β-lactamases drive global Enterobacterales TZP resistance and raise MICs to the clinical breakpoints, making susceptibility testing challenging. In 2022, CLSI revised the Enterobacterales TZP MIC breakpoints. Due to the lack of contemporary correlates, disk diffusion breakpoints were revised using outdated historical data from 1991 and 2003 and yielded unacceptable error rates. Additionally, there is a lack of global consensus on disk potency. The EUCAST TZP disks contain 30 μg piperacillin and 6 μg tazobactam. The CLSI disks, established after TZP approval in 1979 and prior to the widespread prevalence of ESBLs, contain 100 μg piperacillin and 10 μg tazobactam. Here, we evaluate disk diffusion using the 100/10 and 30/6 μg TZP disks with 100 contemporary Enterobacterales isolates, including 40 harboring blaOXA-1. We conducted a disk development study to determine if an alternative potency might address accuracy issues with TZP susceptibility testing. We demonstrate that decreasing TZP potency improves the performance of disk diffusion and improves separation between susceptible and non-susceptible isolates, particularly those harboring OXA-1, but no disk yielded optimal results. The alternative 20/5 μg disk yielded the lowest errors using CLSI MIC breakpoints and the best separation between susceptible isolates and isolates harboring blaOXA-1. Our study addresses an unmet need, shows that further optimization of the TZP disk potency is possible, and provides clinical laboratories with a better understanding of the performance of TZP disks using contemporary, challenging isolates. A larger, multicenter study is needed for further optimization but has been limited by a lack of funding for an off-patent antimicrobial. Our struggles in accessing funding underscore the frequent challenge with AST for older but heavily used antimicrobials.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Khan A, Manuel C, Maynard R, et al. Evaluation of piperacillin-tazobactam disks using contemporary Enterobacterales isolates suggests the need for disk potency optimization. J Clin Microbiol. 2025. PMID: 39791897. doi:10.1128/jcm.01599-24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。